Glycemic and Metabolic Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes: A Single-Centre Clinical Audit
https://doi.org/10.15605/jafes.041.S1
- Author:
Shinye Eng
1
;
Rabeah Md Zuki
1
Author Information
1. Hospital Sultan Abdul Halim
- Publication Type:Journal Article
- MeSH:
Diabetes Mellitus, Type 2;
Glucagon-Like Peptide-1 Receptor Agonists;
Clinical Audit
- From:
Journal of the ASEAN Federation of Endocrine Societies
2026;41(S1):44-
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
improve glycemic control, promote weight loss, reduce
insulin requirements, and confer cardiometabolic benefits
in type 2 diabetes mellitus (T2DM). This audit evaluated
glycemic and metabolic outcomes of GLP-1 RAs in T2DM
patients at a single-centre diabetes clinic.
Methodology:This audit included T2DM patients who initiated GLP1 RAs between January 2022 and March 2025 at Hospital
Sultan Abdul Halim. Primary outcomes were changes in
hemoglobin A1c (HbA1c), body weight, and body mass
index (BMI) at 3 and 12 months. Secondary outcomes
included percentage weight loss, changes in systolic blood
pressure (SBP), insulin total daily dose (TDD), low-density
lipoprotein (LDL) cholesterol, gastrointestinal adverse
effects, and treatment discontinuation.
Results:Sixteen patients were included; median age was 58.5 years
(interquartile range [IQR] 47.5–65), and 56.3% were female.
Median diabetes duration was 15 years (IQR 11.5–20.3).
Median HbA1c decreased from 9.7% (IQR 8.6–10.4) at
baseline to 8.8% (IQR 7.7–9.1) at 3 months and 7.8% (IQR
7.0–8.5) at 12 months. Body weight decreased from 88.1 kg
(IQR 79.5–122.1) at baseline to 85.0 kg (IQR 75.9–113.7) at
3 months and 82.0 kg (IQR 74.8–117.3) at 12 months. BMI
decreased from 37.8 kg/m² (IQR 31.7–47.1) to 37.3 kg/m²
(IQR 30.7–45.5) at 3 months and 36.0 kg/m² (IQR 30.1–45.6)
at 12 months.
At 12 months, weight loss was 5.8% (IQR 3.0–8.0), with
56.5% achieving >5% weight reduction. In all, 93.8%
achieved >1% HbA1c reduction. Mean SBP decreased by
10 ± 20 mmHg, LDL cholesterol 0.29 mmol/L (IQR -0.77
to 0.07), and insulin TDD 8 units/day (IQR -13 to 10). No
gastrointestinal adverse effects reported. Three patients
(18.8%) discontinued treatment due to excessive weight
loss, treatment plateau, and limited drug availability.
Conclusion:From our single-centre experience, the observed improvements in glycemic and metabolic outcomes support the
benefits of GLP-1 RAs in managing T2DM.
- Full text:2026073010363280177EP_A044.pdf
